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Abstract 
MRI is one of the most important imaging tools in clinics. It interrogates nuclei of atoms in a 
living subject, providing detailed delineation with high spatial and temporal resolutions. To 
compensate the innate low sensitivity, MRI contrast probes were developed and widely used. 
These are typically paramagnetic or superparamagnetic materials, functioning by reducing 
relaxation times of nearby protons. Previously, gadolinium(Gd)-based T1 contrast probes 
were dominantly used. However, it was found recently that their uses are occasionally as-
sociated with nephrogenic system fibrosis (NSF), which suggests a need of finding alternatives. 
Among the efforts, manganese-containing nanoparticles have attracted much attention. By 
careful engineering, manganese nanoparticles with comparable r1 relaxivities can be yielded. 
Moreover, other functionalities, be a targeting motif, a therapeutic agent or a second imaging 
component, can be loaded onto these nanoparticles, resulting in multifunctional nanoplat-
forms. 
Key  words:  nanomedicine;  MRI;  manganese;  contrast  probes;  nanoparticles;  tumor  imaging; 
theranostics. 
Introduction 
MRI  is  an  imaging  technique  that  interrogates 
nuclei of atoms inside a living body. It is one of the 
most frequently used imaging tools in daily clinics, 
allowing diagnosis to be performed in a noninvasive 
and real-time manner [1]. Its excellent soft tissue con-
trast makes it a complement to many other imaging 
modalities,  such  as  computed  tomography  (CT),  to 
afford both anatomical and functional information [2].  
While blessed with an innate high resolution, the 
low sensitivity of MRI often times compromises di-
agnosis  quality.  In  order  to  improve  visibility,  con-
trast  agents  of  various  forms  have  been  developed 
and used [3-5]. These agents, functioning by shorten-
ing relaxation times of nearby protons, improve the 
contrast  between  lesions  and  normal  tissues.  This 
leads to better imaging quality and a reduced risk of 
misdiagnosis.  In  clinics,  the  most  frequently  used 
contrast  agents  are  gadolinium  (Gd)-based  agents 
[6-8].  Due  to  an  extremely  high  toxicity,  Gd-based 
agents are always given in a chelated form. However, 
several cases of nephrogenic systemic fibrosis (NSF) 
have  been  reported  recently  on  patients  taking 
Gd-based contrast agents [9-11]. This once again rais-
es concerns over the safety of this class of probes [12, 
13] and therefore, spurring a new wave of exploit for 
non-Gd replacements [14]. As a metal ion with com-
parable T1 contrast ability, Mn and its derivatives are 
regarded  as  promising  alternatives.  As  a  matter  of 
fact,  Mn-based  agents  have  shown  better  perfor-
mances than Gd-based ones in certain disease detec-
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tion, such as for pancreatic lesions [15]. 
The emergence of nanoparticle-based materials 
has added fuel to such an effort. With a size of several 
to hundreds of nanometers, nanomaterials are signif-
icantly  larger  than  small  molecules,  allowing  the 
loading of multiple copies of them. On the other hand, 
they are small enough to pass through many biologi-
cal barriers and able to interact with a biological sys-
tem  at  the  molecular  level.  Through  decades  of  re-
search, it is believed that the technology has evolved 
to  a  level  that  allows  the  construction  of  nanoscale 
materials in a controlled manner. We can now syn-
thesize  nanoparticles,  by  chemical,  physical  or  bio-
logical means, with accurate control over many pa-
rameters, including their size, shape, composition and 
surface  nature.  Tailoring  these  parameters,  in  turn, 
gives us the ability to tune particles’ physical proper-
ties, such as their ability to induce contrast in MRI. 
Previously, iron oxide nanoparticles have been stud-
ied  as  T2/T2*  contrast  agents  [16-20],  especially  for 
imaging reticuloendothelial system (RES) organs like 
the liver, spleen and lymph nodes [4, 19]. However, 
iron oxide nanoparticles induce hypointensities. Such 
a  negative  contrast  may  be  confused  with  areas  of 
innate hypointensities, such as hemorrhage and blood 
clots, or interfered with magnetic susceptibility arti-
facts [21]. Both kinds of inferences can lead to inac-
curate  diagnosis.  Mn  nanoparticle-based  contrast 
agents, on the other hand, induce more favorable hy-
perintensities on a T1-weighted map [22-24]. The re-
lated exploits are more recent but have attracted much 
attention. In this review article, we will discuss the 
recent progress in this field, with an emphasis on how 
to engineer nanoparticles to achieve a higher r1 relax-
ivity.  
2. Types of Mn-based nanoparticles 
2.1 Manganese oxide nanoparticles 
Many approaches have been developed to syn-
thesize manganese oxide (MnO or Mn3O4) nanoparti-
cles. One common route is to heat up oleate-Mn in a 
high  boiling  point  solvent  (e.g.  1-octadecene)  to  in-
duce  nucleation  and  particle  growth  [25].  Such  a 
method allows the preparation of nanoparticles with 
accurate  size  control.  In  one  of  these  reports,  it  is 
shown that MnO nanoparticles from 7 to 25 nm can be 
prepared  in  large  scale.  One  major  disadvantage, 
however, is  the  water insolubility of as-synthesized 
products. Those nanoparticles are surface-passivated 
with a layer of oleic acid, and therefore, are highly 
hydrophobic. To address this issue, a surface modifi-
cation  step  is  needed,  which  transfers  the 
as-synthesized nanoparticles to a water phase. In fact, 
this is a common problem shared with many other 
kinds  of  nanoparticles  prepared  through  high  tem-
perature decomposition. Likewise, the phase transfer 
methods are in many cases interchangeable [19].  
Unlike  T2/T2*  contrast  agents,  the  T1  contrast 
agents need to have direct interaction with the sur-
rounding  water  protons  to  affect  their  relaxation 
times. For nanospheres, it means that only Mn ions on 
the  surface  are  effective.  With  the  same  amount  of 
Mn, smaller nanoparticles tend to have a larger sur-
face percentage and therefore, higher  r1 relaxivities. 
Indeed,  when  using  phospholipids  as  the  coating 
materials to transfer Mn nanoparticles into an aque-
ous solution, it was found that the 7 nm formulation, 
the smallest among all tested, has the highest r1. In a 
clinical 3.0 T magnet, r1 relaxivities were evaluated to 
be 0.37, 0.18, 0.13 and 0.12 mM-1s-1 for Mn nanoparti-
cles with a diameter of 7, 15, 20 and 25 nm, respec-
tively. In a separate study, Huang et al. used manga-
nese  stearate  as  the  precursor  and  prepared 
MnO/Mn3O4  nanoparticles  by  hydrothermal  de-
composition. It was reported that nanoparticles down 
to 5 nm can be prepared by such a method, and the r1 
was found over 1 mM-1s-1[26]. Further down this path, 
Baek  et  al.  prepared  MnO  nanoparticles  of  2-3  nm 
using  triethylene  glycol  as  the  solvent  and 
D-glucuronic acid as the coating material. The result-
ant MnO nanoparticles can have an r1 as high as 7.02 
mM-1s-1[27]. 
Aside from the size effect, the coating material 
that  stands  between  particle  surface  and  the  sur-
roundings is considered another important factor. For 
instance, Huang et al. used a dopamine-plus-human 
serum albumin (HSA) bilayer coating to make MnO 
nanoparticles water soluble [23]. In the first step, do-
pamine,  with  its  adjacent  hydroxyl  groups,  tightly 
bound with surface Mn to replace the original oleate 
coating. Subsequently, a layer of HSA was adsorbed 
onto  the  nanoparticle  surface  to  bring  in  sufficient 
water dispensability (Figure 1). From the same batch 
of as-synthesized MnO nanoparticles, they then used 
both dopamine-plus-HSA and phospholipids to make 
MnO nanoparticles water soluble. It was found that 
particles yielded from the former strategy induced an 
r1 that is over five times higher than from the latter, 
phospholipid-coated one (1.97 vs. 0.37 mM-1s-1 for 20 
nm  MnO  nanoparticles).  Although  the  detailed 
mechanism is unknown, it is believed that the more 
hydrophilic bilayer is essential. Unlike in the case of 
phospholipids, where a hydrophobic zone exists be-
tween particle surface and the aqueous surroundings, 
both  dopamine  and  HSA  are  hydrophilic  materials 
and allows efficient water penetration.  Theranostics 2012, 2(1) 
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Figure 1. a) Schematic illustration of the dopamine-plus-HSA coating strategy. b) Phantom studies with nanoparticles 
coated with HSA (the first row) and phospholipids (the second row). At the same Mn concentration, HSA coated MnO 
nanoparticles showed much higher hyperintensities. Reproduced with permission from Ref. [23]. 
 
 
The advanced synthetic technology also allows 
the  preparation  of  composite  nanoparticles.  For  in-
stance, the synthesis of Au-MnO nanoparticles with 
either  a  flower-like  shape  or  a  dumbbell-like  shape 
was reported [28, 29]. It typically starts with Au na-
noparticles, and subsequently grows MnO petals on 
top of these seeds. Schladt et al. used a multidentate 
copolymer carrying catechol anchors and PEG linkers 
to  replace  the  original  hydrophobic  coating  on 
Au-MnO nanoflowers. The resulting nanoparticles are 
water soluble and showed an r1 of 0.224 mM-1s-1. Such 
a relatively low r1 can be explained by the fact that a 
large part of MnO is hinged with Au nanoparticles 
and is not accessible to water. An advantage of using 
such  a  composite  nanostructure  is  that  it  has  two 
surface types and can be functionalized dually. While 
the MnO have high affinity with catechol and its de-
rivatives, the Au particles can be easily modified with 
thiolated species. In theory, two types of functionali-
ties can be loaded without causing cross-species in-
terference.  As  a  proof-of-concept  study,  4-chloro-7- 
nitrobenzofurazan  (NBD)  and  a  Texas  red  tagged 
24-mer oligonucleotide were loaded separately onto 
the  MnO  and  Au  surface  of  Au-MnO  nanoflowers 
[29]. 
2.2 Hollow manganese oxide nanoparticles 
As mentioned above, an increased nanoparticle 
surface percentage can lead to a higher r1. Instead of 
reducing the nanoparticle  size, it is also possible to 
achieve this goal by converting particles into a hol-
lowed  structure. It was reported that  treating MnO 
nanoparticles at high temperature (300 ˚C) in technical 
grade  trioctylphosphine  oxide  can  lead  to  the  for-
mation  of  MnO  nanohollows.  It  was  later  revealed 
that  the  impurities,  mostly  alkylphosphonic  acid, 
were playing a role as an etching agent [30]. Further 
characterizations  found  that  an  inward  diffusion  of 
phosphorus and an outward diffusion of manganese 
took place in the intermediate stages during the etch-
ing,  a  so-called  Kirkendall  effect.  This  generated  a 
void within the original nanoparticle (Figure 2). The 
resultant nanostructures retained the size and shape 
uniformity of the original nanocrystals but have sig-
nificantly  increased  water  accessibility.  For  20  nm 
MnO  nanoparticles,  this  treatment  can  increase  r1 
from 0.353 to 1.15 mM-1s-1.  
An alternative  way of forming MnO hollowed 
nanostructures is to incubate water soluble MnO na-
noparticles in a phthalate buffer (pH 4.6, r.t.) for 12 h. 
This will not affect the coating but will etch away part 
of the MnO interior to induce a void. For 20 nm MnO 
NPs, it was reported that an r1 as high as 1.42 mM-1s-1 
can be achieved [31]. 
2.3. Silica-coated manganese oxide nanoparticles 
Instead  of  adopting  an  organic  coating,  MnO 
nanoparticles can also be coated with a layer of silica. Theranostics 2012, 2(1) 
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There are at least two folds of merits with silica coat-
ings. First, silica is a biocompatible material. Second, 
silica coating allows easy functionality loading, either 
onto the particle surface or into the silica framework. 
Dyes, photosensitizers and many other kinds of func-
tionalities can be pre-conjugated with silane deriva-
tives,  such  as  3-aminopropyltrimethoxysilane 
(APTMS), and loaded at high rate into silica matrices. 
However, intact silica coating is too dense to allow 
efficient  water  infiltration.  To  overcome  this  issue, 
Peng et al. developed an etching process to induce a 
mesoporous structure and to improve water permea-
bility.  It  was  achieved  by  incubating  silica-coated 
MnO  nanoparticles  with  ethylacetate  and  sodium 
hydroxide at 60˚C. Such a mesoporous structure al-
lows water molecules to move in through the pores 
and interact with the surface Mn (MnO@mSiO2). More 
excitingly, further treatment under this condition can 
lead to corrosion of the imbedded MnO cores, gener-
ating hollowed cores (H-MnO@mSiO2). As mentioned 
above, this hollowed structure can further improve r1 
relaxivites.  Indeed,  MnO  nanoparticles  with  intact 
silica coatings only have an r1 of 0.07 mM-1s-1. Such a 
figure  was  found  increased  to  0.16  mM-1s-1  for 
MnO@mSiO2 and 0.2 mM-1s-1 for H-MnO@mSiO2 [32]. 
In a separate study, Kim et al. used a different 
approach to induce porous structure. They introduced 
cetyl  trimethylammonium  bromide  (CTAB)  along 
with  tetraethyl  orthosilicate  (TEOS)  during  a  silica 
sol-gel reaction process. CTAB served as the organic 
structure-directing template [21]. Later on, when in-
cubated in refluxing ethanol solutions (pH = 2.4), such 
a CTAB template was removed, leaving pores in the 
silica matrices (Figure 3). Like in the above case, such 
a treatment in acid environment also led to the for-
mation of a hollowed nanostructure. For 15 nm MnO 
nanoparticles,  it  was  reported  that  an  r1  of  1.72 
mM-1s-1  can  be  achieved.  The  resulting  mesoporous 
silica-coated  hollow  manganese  oxide 
(HMnO@mSiO2) nanoparticles are able to efficiently 
label adipose-derived mesenchymal stem cells (MSCs) 
and to facilitate the tracking of MSCs in vivo by MRI 
(Figure 3).  
Compared with MnO nanohollows with an or-
ganic coating, it is obvious that the silica coated ones 
have slightly lower r1 relaxivities. This is not surpris-
ing considering a higher surface coverage rate of the 
latter.  On  the  other  hand,  silica  coating  affords  a 
scaffold effect which stabilizes the nanohollow struc-
ture. This brings a better morphology control and less 
worry  on  the  nanostructure  collapse.  Last  but  not 
least,  the  well-established  silica  engineering  tech-
niques  allow  the  easy  loading  of  various  types  of 
functionalities. Organic dyes, inorganic fluorophores, 
small molecule drugs, peptides, antibodies and siR-
NA have all been loaded onto silica coated nanopar-
ticles, independent of the nature of cores [19, 33]. 
 
Figure 2. TEM images taken a) before 
and b) after the etching process. Voids 
were  generated  inside  the  nanostruc-
tures. c) Suggested  mechanism for the 
generation of voids. An inward diffusion 
of phosphorus and an outward diffusion 
of  manganese  took  place  at  the  same 
time, leading to the formation of a void in 
the  nanostructure.  Reproduced  with 
permission from Ref. [30]. Theranostics 2012, 2(1) 
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Figure 3. Characterizations of HMnO@mSiO2 nanoparticles. a) TEM image. b) HRTEM image of a single nanoparticle. 
c) T1 map of HMnO@mSiO2 nanoparticles suspended in water at 11.7 T. d) Plot of 1/T1 versus Mn concentration. The slope 
indicates the specific relaxivity (r1). e-f) In vivo MRI of transplanted MSCs. e) No hyperintense signal (red arrow) was detected 
in mouse transplanted with unlabeled MSCs. f) Hyperintense signals (green arrows) were detected in mouse transplanted 
with HMnO@mSiO2-labeled MSCs and were still detectable 14 days after the injection. Reproduced with permission from 
Ref. [21]. 
 
2.4. Mn-doped nanoparticles and nanoscale met-
al-organic frameworks 
Instead of engineering  manganese  oxide  nano-
particles,  it  is  also  possible  to  arrive  at  Mn-based 
probes  by  doping  free  Mn  cations  or  incorporating 
Mn  complexes  into  other  nanoscaffolds.  Previously, 
Niesman et al. has loaded MnCl2 into liposomes and 
used them as liver specific contrast agents [34]. It was 
shown from toxicity studies that the effective dose of 
such a complex was 7 to 11 times lower than the LD50 
of  free  MnCl2.  In  rats  with  implanted  liver  tumors, 
those particles induced a two- to three-fold increase in 
the relaxation rate of liver while having little effect on 
the tumor relaxation rate, making this formulation a 
potential contrast agent for liver metastasis imaging 
[34]. In a separate study, Pan et al. loaded Mn(III), in 
the form of a porphyrin complex, onto a nanobialy 
constructed  by  amphiphilic  branched  polyethyl-
enimine  (PEI)  [35].  Such  an  amphiphilic  PEI  was 
achieved  from  alkylating  PEI10k  with  linoleic  acid. 
The  resultant  PEI  can  self-assemble  into  a  toroidal 
shape  with  low  polydisperisity.  Mn(III)- 
protoporphyrin chloride (Mn-PPC) can be easily in-
corporated  into  such  an  inverted  micellar  structure 
(Figure 4). Most Mn-PPC was found at the surface of 
the nanostructure, a feature that is essential for water 
accessibility. Under a 1.5 T magnet, an r1 of 3.7 mM-1s-1 
was recorded. Such a nanobialy structure can be fur-
ther  loaded  with  small  drug  molecules,  such  as 
camptothecin or doxorubicin, with high efficiency (98 
± 0.1 % and 99 ± 0.1% for doxorubicin and camptoth-
ecin, respectively). It is therefore regarded as a poten-
tial theranostic nanoplatform, having both diagnostic 
and therapeutic values. Another example is Mn-oleate 
based  nanocolloids  reported  by  Pan  et  al.  In  brief, 
Mn-oleate was suspended with polysorbates (e.g. sor-
bitan sesquioleate) and homogenized with a mixture 
of surfactants, mainly comprised of phosphatidylcho-
line  (PC)  (~90  mol%)  and  biotin-caproyl-PE  (~1%). 
This leads to the formation of a nanocolloid with a 
hydrodynamic  size  of  134  ±  2  nm.  Under  a  3.0  T 
magnet,  the  r1  was  evaluated  to  be  14.6  ±  1.1 
mM-1s-1[36]. 
Recently,  silicon-based  quantum  dots  (QDs) 
have attracted much attention. Compared to the pre-
viously used QDs, Si QDs are more favorable for their Theranostics 2012, 2(1) 
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better  biocompatibility  and  biodegradability  [37].  It 
was reported recently that Mn can be doped into such 
a  system  to  achieve  probes  with  MRI/optical  dual 
functionalities.  For  preparation,  a  high-energy  mill 
was  used  to  ball-mill  mixtures  of  NaH,  Si  and  Mn 
powders  with  an  appropriate  molar  ratio.  Such  a 
mixture was placed into an alumina crucible with a lid 
which  was  placed  into  a  quartz  tube.  It  was  then 
heated  at  420˚C  for  2  days  followed  by  heating  at 
500˚C  for  1  additional  day  under  flowing  nitrogen. 
The yielded sodium silicide (Mn-doped) was used as 
a precursor and heated to reflux for 2h in DMF with 
the presence of NH4Br and allylamine. The resultant 
nanoparticles can be dispersed in water and can be 
further stabilized by adding a dextran sulfate or dex-
tran coating. Two-photon excitation found a peak at 
790  nm,  which  is  in  the  near-infrared  region  and 
therefore, has optimum tissue penetration. These na-
noparticles demonstrated a very high r1 relaxivity at 
25.50 ± 1.44 mM-1s-1[38]. 
Recently,  Mn-containing  metal-organic  frame-
work was constructed by Taylor et al. and was studied 
as  an  MRI  contrast  probe  [39].  Unlike  the 
above-mentioned nanocrystals, such a nanostructure 
is not metal-oxide-based. It was synthesized by using 
either terephthalic acid (BDC) or trimesic acid (BTC) 
as a bridging ligand. Then through a reverse-phase 
microemulsion  process,  Mn(II)  complexed  with  the 
bridging ligands and grew into a nanorod structure 
(Figure  5).  These  nanoparticles,  too,  can  be  easily 
coated with silica and further loaded with other func-
tionalities. The resultant nanoparticles demonstrated 
good r1 relaxivities (5.5 mM-1s-1 under 3.0 T and 4.6 
mM-1s-1 under 9.4 T). 
3. Multifunctional manganese oxide nano-
particles 
Like  many  other  nanoplatforms,  Mn  particles 
can be coupled with different kinds of functionalities 
and  upgraded  to  multifunctional  nanogadgets.  For 
instance, it is possible to conjugate a targeting motif, 
such as a peptide [40, 41] or an antibody [4], onto na-
noparticles to gift them targeting specificity. In one of 
these studies, MnO nanoparticles were coupled with 
Herceptin, an antibody that targets human epidermal 
growth factor receptor 2 (HER2) [42, 43]. The conju-
gates, after i.v. injected, were able to home to breast 
cancer metastasis in the brain. It is believed that the 
blood brain barrier (BBB), which blocks the infiltration 
of particles into the brain, was destructed at the tumor 
site.  While  both  non-functionalized  and  functional-
ized nanoparticles can penetrate BBB, only the Her-
ceptin conjugated ones were able to home to the tu-
mor sites. 
It is also possible to put other imaging compo-
nents  onto  nanoparticles  to  achieve  multimodality 
imaging probes. It was mentioned above that Mn can 
be doped into a silicon QD matrix to achieve dually 
functional imaging probes with both MRI and optical 
imaging capabilities. From an in vitro analysis, they 
found that these nanoparticles can be efficiently taken 
up  by  macrophages  without  dramatically  affecting 
the  cells’  viability.  The  particle-labeled  cells  can  be 
easily recognized by both MRI and two-photon opti-
cal imaging, suggesting their potential as cell labeling 
reagents [38].  
Therapeutics of various forms can also be loaded 
onto  Mn-based  nanoplatforms.  Choi  et  al.  loaded 
doxorubicin,  via  electrostatic  interaction,  onto  silica 
coated MnO nanoparticles. These nanoparticles were 
further loaded into a 3-D  poly(propylene fumarate) 
(PPF) scaffold. It was found that the release of doxo-
rubicin into the surroundings can be tracked by both 
MR and optical imaging [44]. Shin et al. demonstrated 
that doxorubicin can be loaded into hollow MnO na-
noparticles at 202 µg/mole particle, a rate which is 
much higher than into intact MnO nanoparticles (58 
µg/mole particle). Doxorubicin is amphiphatic, and in 
principle a hydrophobic molecule. It is believed that 
the  hydrophobic-hydrophobic  interaction  between 
doxorubicin  and  the  oleic  acid  coating  is  the  main 
cause of the loading. With higher oleic acid coverage, 
the hollowed nanostructure affords a higher coating 
capacity [31].  
In  another  important  study,  Viglianti  et  al. 
loaded both MnSO4 and doxorubicin into a liposome 
formulation (Figure 6). It is believed that two doxo-
rubicin molecules are coordinated to each Mn2+ cation 
within  the  liposome,  where  water  molecules  have 
limited accessibility. The release of Mn into the sur-
roundings  is  found  associated  with  significant  T1 
shortening and this feature was studied as a means to 
monitor the in vivo drug release. The drug release was 
triggered by inducing heat to tumors. When using a 
thermal sensitive liposome formulation, it was found 
clearly that the drug release occurred preferentially at 
the periphery of tumors (Figure 6). This pattern was 
concordant with the release temperature of the for-
mulation (39-40˚C). As a control, a nonthermally sen-
sitive  formulation  was  also  tested.  While  selective 
tumor accumulation was also observed, a heteroge-
neous drug distribution pattern was found in such a 
case [45]. Later on, the same group studied whether 
the timing of liposome administration is critical to the 
drug release. It was found that doxorubicin was ac-
cumulated more rapidly and efficiently if the formu-
lation was injected during rather than before the hy-
perthermia [46].  Theranostics 2012, 2(1) 
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Figure 4. Linoleic acid modified PEI can self-assemble into a toroidal shape nanostructure. Mn(III)-protoporphyrin chloride 
(Mn-PPC) was able to be incorporated into such an inverted micellar structure. Under a 1.5 T magnet, an r1 of 3.7 mM
-1s
-1 
was recorded. Reproduced with permission from Ref. [35]. 
 
 
 
Figure 5. SEM images of a) Mn(BDC)(H2O)2 nanorods and b) Mn3(BTC)2(H2O)6 spiral nanorods. c) Nanorods can be 
surface-functionalized with PVP and then coated with a thin layer of silica. Other functionalities, such as peptides and dye 
molecules, can be as well loaded onto the silica coating. Reproduced with permission from Ref. [39]. Theranostics 2012, 2(1) 
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Figure 6. a) Schematic depiction of a temperature-sensitive liposome containing doxorubicin (Dox) and contrast agent 
(manganese sulfate, MnSO4). The phospholipid bilayer undergoes a main melting phase transition at 41 °C, which leads to the 
release of contents. DPPC = 1,2 dipalmitoyl-sn-glycerol-3-phosphocholine; MSPC = 1-stearoyl-2-hydroxy-sn-glycero-3- 
phosphocholine. b-e) MRI axial images of rats with transplanted flank fibrosarcomas treated with doxorubicin/Mn containing 
liposomes. b) LTSL with HT, c) LTSL without HT, d) NTSL with HT, and e) NTSL without HT from 0-90 min. LTSL = 
lysolipid-based temperature-sensitive liposomes; HT = hyperthermia; NTSL = non-temperature-sensitive liposomes. Re-
produced with permission from Ref. [45] and [46]. 
 
Very recently, Bae et al. demonstrated the possi-
bility of loading siRNA onto hollow MnO nanoparti-
cles.  They  coupled  3,4-dihydroxy-L- 
phenylalanine with  polyethylenimine(PEI)  and  used 
the  resultant  conjugate  as  an  adhesive  moiety  to 
modify  the  hollow  MnO  particle  surface.  Herceptin 
was  loaded  via  chemical  conjugation.  On  the  other 
hand,  siRNA  was  loaded  by  electrostatically  inter-
acting  with  the  polycation  coating.  They  demon-
strated at the in vitro level that the resultant conjugates 
can selectively target HER2 overexpressed cells and 
induce silencing of the target gene [47]. 
4. Toxicity 
One major concern of using Mn-based nanopar-
ticles is their cellular toxicity. Manganese is consid-
ered  as  an  essential  metal  for  biological  systems, 
working as a cofactor for a number of key enzymes 
[48, 49]. However, high concentrations of Mn is asso-
ciated  with  neurotoxicity.  This  includes  progressive 
and  permanent  neurodegenerative  disorders,  alto-
gether termed as manganism, which resembles Par-
kinsonism  in  many  ways  [50,  51].  Nonetheless,  Mn 
formulations have been used frequently in clinics to 
help improve the quality of MR imaging. MnCl2, for 
instance, is an FDA approved contrast agent. Due to 
its  ability  to  enter  excitable  cells  through  volt-
age-gated calcium channels, it is widely used in MRI 
to demarcate active regions of the brain  [52, 53]. In 
small animal studies, it was recommended that doses 
higher than 93 mg/kg and 38 mg/kg should not be 
used for rats and mice, respectively [54]. However, a 
much higher dose was used with manageable adverse 
effects [55, 56]. Chelated Mn is considered much safer 
than free Mn(II). Mangafodipir trisodium (MnDnnP), 
for instance, is another FDA approved formulation, 
used extensively in hepatobiliary MRI  [57, 58]. It is 
believed that its structural similarity to vitamin B6 is 
one of the main factors for its high hepatocyte uptake 
[59]. It is noted, however, that Mn(II) can be released 
from  the  complex  through  metabolism.  Those  re-
leased cations accumulate in the liver, pancreas and 
cardiac  muscle  and  cause  hyperintensities.  At  sug-
gested  does,  however,  those  released  Mn  will  not 
cause dramatic side effects.  
On the other hand, relatively little attention has 
been paid to the toxicity of Mn-doped nanoparticles. 
So far, most research in this area has been satisfied 
with in vitro viability assays. It was claimed by many 
that Mn-doped nanoparticles, be a silica matrix or a 
metal-organic  framework,  are  safer  than  Mn  chela-
tors, since the Mn are less likely released during cir-
culation. However, these nanoparticles, with a larger 
size, cannot be secreted through renal clearance and 
may stay in a living subject for a long period of time. 
What is the metabolism route and how the daughter 
compounds interact with a biological system is largely 
unknown at this point. A similar issue was found in Theranostics 2012, 2(1) 
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the research on manganese oxide-based formulations. 
One common argument is that Mn is in a crystallized 
form in MnO or Mn3O4 nanoparticles and does not 
easily  fall  off.  Indeed,  viability  studies  have  shown 
that cells can tolerate these nanoparticles to a certain 
degree. MnO nanoparticles have even been used for 
labeling and tracking transplanted cells [60]. Howev-
er, cytotoxicity studies provide limited information on 
the long-term impact. At the end of the analysis (typ-
ically within 72 h), many nanoparticles are still in the 
process  of  decomposing  in  an  acidic  endo-
some/lysosome environment. Systematic studies are 
needed to better understand the detailed particle me-
tabolism and their long-term effects to a living subject, 
especially from a neurotoxicity perspective. 
5. Conclusions and perspective 
Mn-based nanoparticles are a relative new class 
of materials. Unlike the other well-studied nanoparti-
cles, such as iron oxides [61], research on Mn-based 
nanoparticles is at a relatively early stage. Much more 
work has to be done to promote this new class of ma-
terials in a nanomedicine context. Several key param-
eters include their T1 contrast ability and their distri-
bution  in  a  living  subject,  either  with  or  without  a 
targeting motif.  
To estimate their translation potential, more ef-
forts  should  be  put  on  accessing  the  biosafety  of 
Mn-based  nanoparticles.  The  current  analy-
sis-of-standard is in vitro viability assay [62]. At this 
stage, little is known about the nanoparticles’ metab-
olism and the long-term side effects to a living subject. 
Also, it is worthwhile to perform a side-by-side com-
parison with both Gd- and iron oxide-based formula-
tions to assess the advantages of Mn-based nanopar-
ticles, if there is any. 
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